This investment joins Peregrine’s growing portfolio of cancer-related companies.
KAHR develops smart immune-recruitment cancer drugs that activate a targeted immune response by converting cancer camouflage into beacons for the immune system to attack.
KAHR is a clinical-stage company developing novel immune-recruiting therapies that treat cancer at the source by unleashing the synergistic power of the body’s innate and adaptive immune responses.
The company is leveraging its proprietary MIRP technology to promote better and safer therapeutic avenues by developing new immuno-recruitment drugs that unmask cancer camouflage mechanisms, while simultaneously recruiting a targeted immune response.
